The purpose of this study is to determine the dosimetry for the Positron Emission Tomography (PET) tracer \[11C\]Cimbi-36 in two different Carbon-11 labelling positions. This information will contribute to determining whether \[11C\]Cimbi-36 can be optimized by changing the C-11 labelling position.
Healthy subjects wil undergo a whole-body Positron Emission Tomography (PET) scan with the Serotonin 2A Receptor (5-HT2A) radioligand \[11C\]Cimbi-36 or \[11C\]Cimbi-36-5 to determine the effective radiation dose and radiation dose for selected organs.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
8
Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark
Effective dose and absorbed dose for selected organs
Based on the Positron Emission Tomography (PET) scan Time activity curves (TACs) will be generated and used for calculating the radiation doses for selected organs and over all effective radiation dose.
Time frame: 0 - 120 minutes
Measurement of radioactive metabolites in plasma
Venous blood samples will be used to measure radioactive metabolites and parent compound in the blood, using radio-High-performance liquid chromatography (HPLC). The parameters will be parent radioactivity and metabolite radioactivity as a fraction (unitless) of total radioactivity in plasma over time (unit = minutes).
Time frame: 0 - 120 minutes
Measurement of radioactivity in plasma and whole blood
Venous blood samples will be used to measure radioactivity in plasma and whole blood. The measurement will be given as a ratio (unitless) of plasma radioactivity relative to whole blood radioactivity over time (unit = minutes).
Time frame: 0 - 120 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.